Dapagliflozin in STEMI

Sponsor
Ottawa Heart Institute Research Corporation
Study ID
NCT06174753
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Myocardial Infarction
  • ST Elevation Myocardial Infarction

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Dapagliflozin 10mg Tab — DRUG
    Dapagliflozin 10 mg daily X 7 days
  • CMR — DIAGNOSTIC_TEST
    CMR 3-5 days post randomization

Study Details

The goal of this clinical trial is to assess the safety and efficacy of SGLT2i in limiting infarct size in patients with STEMI referred for PPCI. Eligible STEMI patients enrolled into the trial will be randomized to a SGLT2i or placebo. Cardiovascular Magnetic Resonance (CMR) imaging will be used to determine the infarct size.

Key Dates

Start date
Jan 20, 2025
Status verified
Feb 2026
Primary completion
Jun 30, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
256 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment
    Dapagliflozin 10mg daily X 7 days
  • Placebo Comparator: Placebo
    Placebo daily X 7 days

Primary Outcome Measure

Infarct Size [ Time Frame: 3-5 days ]

Central Contacts

Related Studies